SEC Form 4 · accession 0000880771-15-000070
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hong Zhao
Officer — CEO, China Operations
Period of report
May 14, 2015
Accepted (ET)
May 18, 2015 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 14, 2015 | M | 12,500 | $0.00 | A | 12,500 | D | |
| Common Stock | May 14, 2015 | S | 12,500 | $9.07 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | May 14, 2015 | M | 12,500 | A | — | — | Common Stock | 12,500 | 25,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F2Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units vested on April 1, 2014, and 25% will vest on April 1, 2015, April 1, 2016, and April 1, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.